Defensive Rotation Out
ABT is dropping sharply while growth-heavy indexes rally, suggesting classic rotation out of defensive healthcare names into riskier assets, with recent CE mark approvals for heart devices failing to offset this sector-level pressure.
Sources: https://www.stocktitan.net/news/ABT/abbott-s-next-generation-amulet-360tm-device-receives-ce-mark-to-cbham622b72s.h
Previous verdicts for ABT
- AI Search: Abbott Rallies on FDA Approval for CardioMEMS Upgrade — 2026-10-05
- ABT Earnings Call Dip — 2026-09-30
- ABT drifts lower quietly — 2026-09-24
- Bond Yields Crush Stocks — 2026-09-11
- FDA news weighs on shares — 2026-09-10
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works